AMGN · Company research
6 upcoming catalysts · 0 phase 2+ trials on file
View Stock opens Yahoo Finance. Prices and performance charts are provided there.
Three MariTide Phase 3 studies in type 2 diabetes to start in 2026, expected during 2026 (no exact date yet). A company milestone for Amgen (MariTide (maridebart cafraglutide) for Type 2 diabetes): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Amgen expects to report results from its Phase 3 study of dazodalibep for Sjogren's disease (systemic and symptomatic Phase 3 studies) in the second half of 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Amgen expects European regulators to decide on Repatha (evolocumab) for Broader use before a first heart attack or stroke (VESALIUS-CV label expansion) in the second half of 2026 (no exact date yet). An approval lets the company start selling it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
TEZSPIRE Phase 3 eosinophilic esophagitis study completion, expected in the second half of 2026 (no exact date yet). A company milestone for Amgen (TEZSPIRE (tezepelumab) for Eosinophilic esophagitis): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
UPLIZNA Phase 3 CIDP study initiation, expected in the second half of 2026 (no exact date yet). A company milestone for Amgen (UPLIZNA (inebilizumab) for Chronic inflammatory demyelinating polyneuropathy): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Amgen expects to report results from its Phase 3 study of MariTide (maridebart cafraglutide) for Chronic weight management in obesity/overweight (MARITIME-1) and obesity with Type 2 diabetes (MARITIME-2) in the first half of 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Amgen presented data on Repatha (evolocumab) for Primary prevention of cardiovascular events (VESALIUS-CV) at a medical meeting in Aug 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
CHMP backs broader Repatha use before a first heart attack or stroke, on Jul 29, 2026. A company milestone for Amgen (Repatha (evolocumab) for Atherosclerotic cardiovascular disease risk reduction): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Amgen presented data on Repatha (evolocumab) for Cardiovascular risk reduction in high-risk diabetes at a medical meeting on Jun 7, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
European regulators approved Amgen’s IMDYLLTRA (tarlatamab) for Extensive-stage small cell lung cancer, second line or later on Jun 1, 2026. The company can now sell it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
FDA CDER proposes withdrawal of TAVNEOS over efficacy and data integrity, on Apr 27, 2026. A company milestone for Amgen (TAVNEOS (avacopan) for Severe active ANCA-associated vasculitis): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Amgen reported results from its Phase 3 study of TEPEZZA (teprotumumab-trbw) on-body injector for Moderate-to-severe active thyroid eye disease on Apr 6, 2026. The study met its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
FDA flags fatal liver injury cases with Amgen's TAVNEOS, on Mar 31, 2026. A company milestone for Amgen (TAVNEOS (avacopan) for Severe active ANCA-associated vasculitis): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Amgen presented data on Repatha (evolocumab) for Cardiovascular risk reduction in high-risk primary prevention / diabetes at a medical meeting on Mar 28, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Explore reported politician transactions and public investor statements connected to AMGN.
View source-linked activity ↗No phase 2+ trials cached for this company.
No recent headlines on file.